[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, Kallenberg CG, Bootsma H: Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis; 2005 Jun;64(6):958-60
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
  • OBJECTIVES: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.
  • CASE REPORT: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate.
  • Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma.
  • An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue.
  • Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.
  • DISCUSSION: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma.
  • In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS.
  • The efficacy of rituximab in the treatment of SS warrants further investigation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Parotid Neoplasms / drug therapy. Sjogren's Syndrome / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Parotid Gland / immunology. Parotid Gland / physiopathology. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15576414.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1755505
  •  go-up   go-down


2. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M: Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer; 2004 May 15;100(10):2190-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma is a specific clinicopathologic entity with gastric and nongastrointestinal site involvement.
  • The authors reported the clinical outcome of patients with Stage IE nongastrointestinal MALT lymphoma treated with a frontline fludarabine-containing regimen or with a regimen containing cyclophosphamide, vincristine, and prednisone (CVP).
  • Presenting sites included periorbital soft tissue (n = 8), lung (n = 5), skin (n = 5), salivary glands (n = 5), lacrimal glands (n = 5), and thyroid (n = 3).
  • Four patients, all treated with CVP, experienced disease recurrence and then achieved a second CR after FM salvage treatment.
  • No tumor recurrence was observed in patients with thyroid, lacrimal gland, or pulmonary lymphoma.
  • CONCLUSIONS: The fludarabine-containing FM regimen provided a relatively effective frontline (or salvage) treatment option for patients with nongastrointestinal Stage IE MALT lymphoma and probably was superior to CVP in terms of efficacy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA (Cytosine-5-)-Methyltransferase / antagonists & inhibitors. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Gastrointestinal Neoplasms. Humans. Male. Middle Aged. Prednisone / administration & dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139063.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


3. Pachmann S, Anderegg B, Müller-Höcker J, Nathrath W, Brack N, Tigges FJ, Hartenstein R, Munker R: Monoclonal gammopathy after low-grade MALT lymphoma: evidence for a second neoplasm. Am J Hematol; 2002 Jun;70(2):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy after low-grade MALT lymphoma: evidence for a second neoplasm.
  • We report the case of a patient with lymphoma of the salivary gland, at first diagnosed as lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) but later found to infiltrate the bone marrow.
  • At diagnosis, the patient had a polyclonal increase of gamma-globulins.
  • Five years after initial diagnosis, the patient presented with monoclonal gammopathy and infiltration of the bone marrow with neoplastic cells.
  • Initially, the patient had received chemotherapy with different protocols (including etoposide, cyclophosphamide, fludarabin, methotrexate, and vincristine), none of which induced a lasting response.
  • Therapy with rituximab (chimeric anti-CD20 monoclonal antibody) finally led to partial remission.
  • Eighteen months after rituximab, progressive lymphoma in the abdomen and a monoclonal gammopathy developed.
  • The bone marrow showed infiltration by lymphoplasmacytoid cells (monoclonal expression of the light-chain type lambda, positive for CD20, heterogeneous expression of CD45).
  • The patient achieved another short clinical response with 4 cycles of the CHOP-protocol, but soon the lymphoma progressed again.
  • Five years and 8 months after the initial diagnosis, the patient died from septicemia and progressive lymphoma.
  • By polymerase chain reaction (PCR) for the IgH gene it was shown that lymphoma cells were initially oligoclonal in the salivary gland and, later, biclonal in the bone marrow.
  • Sequencing of two bands of apparently same length showed that these manifestations of lymphoma were not identical.
  • Taken together, our data show that the initial low-grade oligoclonal MALT lymphoma was no longer present and a more aggressive biclonal lymphoma with plasmacytoid differentiation had developed.
  • The new lymphoma was clonally distinct and produced high amounts of monoclonal IgG lambda by immunoelectrophoresis.
  • The relationship of the second lymphoma to the initial MALT lymphoma is discussed.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / immunology. Paraproteinemias / etiology. Salivary Gland Neoplasms / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / analysis. Base Sequence. Bone Marrow / pathology. Fatal Outcome. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction. Rituximab. Submandibular Gland / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12111792.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H: Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum; 2005 Sep;52(9):2740-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
  • OBJECTIVE: To investigate the safety and efficacy of B cell depletion treatment of patients with active primary Sjögren's syndrome of short duration (early primary SS) and patients with primary SS and mucosa-associated lymphoid tissue (MALT)-type lymphoma (MALT/primary SS).
  • Inclusion criteria for the early primary SS group were B cell hyperactivity (IgG >15 gm/liter), presence of autoantibodies (IgM rheumatoid factor, anti-SSA/SSB), and short disease duration (<4 years).
  • Inclusion criteria for the MALT/primary SS group were primary SS and an associated MALT-type lymphoma (Ann Arbor stage IE) localized in the parotid gland.
  • Patients were evaluated, using immunologic, salivary/lacrimal function, and subjective parameters, at baseline and at 5 and 12 weeks after the first infusion.
  • RESULTS: Significant improvement of subjective symptoms and an increase in salivary gland function was observed in patients with residual salivary gland function.
  • Human anti-chimeric antibodies (HACAs) developed in 4 of 15 patients (27%), all with early primary SS.
  • Three of these patients developed a serum sickness-like disorder.
  • CONCLUSION: Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Sjogren's Syndrome / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Health Status. Humans. Lacrimal Apparatus / drug effects. Lacrimal Apparatus / physiopathology. Lacrimal Apparatus / secretion. Male. Middle Aged. Parotid Gland / immunology. Parotid Gland / physiopathology. Parotid Neoplasms / pathology. Rituximab. Saliva / secretion. Salivary Glands, Minor / drug effects. Salivary Glands, Minor / physiopathology. Salivary Glands, Minor / secretion. Severity of Illness Index. Tears / secretion. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142737.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


5. Li BZ, Yu CJ, Xu JJ, Lu HF, Shi DR: [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Aug;44(8):651-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas].
  • OBJECTIVE: To study the morphological and genetic characteristics in salivary gland marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) lymphomas.
  • METHODS: Twenty-eight cases of MALT lymphomas of salivary gland were collected from Department of Pathology, Cancer Hospital of Fudan University.
  • In those cases, 18 originated from parotid gland, 6 from submandibular and 4 from sublingual gland.
  • Except surgical resection, patients did not get systematic radio-or chemotherapy.
  • All follow-up time was from 23 to 54 months.
  • CONCLUSIONS: Most salivary MALT lymphomas are arising from parotid glands.
  • The final diagnosis depends on the pathological findings, the number and distribution of monocytoid B cells and clusters of plasmacytoid cells are hints for diagnosis of salivary MALT lymphomas, invasion of blood vessels or nerve also help for malignant diagnosis. t(11;18) and trisomy 18 may be the main chromosomal abnormalities in salivary gland MALT lymphomas, but with low morbidity.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961773.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Shi Q, Zhang T, Xue Q, Fan K, Sun G, Yan X, Shou B, Yu B: Clinicopathologic study of mucosa-associated lymphoid tissue lymphoma of the salivary gland. Chin Med J (Engl); 2001 Jan;114(1):44-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of mucosa-associated lymphoid tissue lymphoma of the salivary gland.
  • OBJECTIVE: To study the histopathologic features and pathogenesis of mucosa-associated lymphoid tissue lymphoma (MALT-oma) of salivary glands.
  • METHODS: Clinical data, paraffin-embedded sections, immunohistochemical slides (SP method) and electron microscopic features of surgical specimens of 32 cases of salivary gland MALT-oma were studied.
  • The lesions were located in the parotid area in 17 cases, and in the submandibular gland in the remaining 15 cases.
  • The cases were managed by surgery and chemotherapy.
  • Hyper-immune reaction and MALT hyperplasia under stimulation may result in myoepithelial sialadenitis and lead to MALT-oma of the salivary gland.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779434.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Ebata K, Masaki Y, Karasawa H, Okada J, Kim CG, Tsuka M, Ogawa N, Wano Y, Hirose Y, Sugai S: [Marginal zone lymphoma associated with Sjögren's syndrome and hepatitis C virus infection]. Nihon Rinsho Meneki Gakkai Kaishi; 2001 Aug;24(4):160-7
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marginal zone lymphoma associated with Sjögren's syndrome and hepatitis C virus infection].
  • A 64-year-old female was admitted in May 1997, because of salivary gland swelling.
  • Histology of the right parotid gland revealed malignant lymphoma, diffuse medium-sized B-cell type, and she was treated with local radiotherapy and chemotherapy.
  • She was rehospitalized in April 1998, because of recurrence of lymphoma in the stomach and the sigmoid colon.
  • A diagnosis of Sjogren's syndrome was made by dryness and the histological findings of labial biopsy.
  • Marginal zone B-cell lymphoma mainly consisted of centrocyte-like cells and lymphoepithelial lesions, and CD 20 and IgM-kappa were positive with immunohistochemical staining.
  • Lymphoma involved the gut and spleen.
  • We discuss the correlation of malignant lymphoma with Sjogren's syndrome and HCV infection.
  • [MeSH-major] Hepatitis C / complications. Lymphoma, B-Cell / etiology. Parotid Neoplasms / etiology. Sjogren's Syndrome / complications

  • Genetic Alliance. consumer health - C Syndrome.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16578967.001).
  • [ISSN] 0911-4300
  • [Journal-full-title] Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • [ISO-abbreviation] Nihon Rinsho Meneki Gakkai Kaishi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


8. Svoboda J, Andreadis C, Downs LH, Miller Jr WT, Tsai DE, Schuster SJ: Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma; 2005 Sep;46(9):1365-8
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection.
  • We describe a patient with chronic hepatitis C virus (HCV) infection who presented with extranodal (right salivary gland and bone marrow) marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).
  • Within a year, the lymphoma progressed to involve peripheral lymph nodes and the liver.
  • After treatment of HCV with peginterferon and ribavirin, he achieved complete radiographic response and remains in remission two years later.
  • This is an example of a patient in whom treatment of HCV infection led to regression of non-splenic, extranodal marginal zone lymphoma.
  • It suggests that HCV testing and treatment should be considered in all patients with marginal zone lymphomas, including non-splenic types.
  • [MeSH-major] Hepatitis C / complications. Hepatitis C / drug therapy. Interferons / therapeutic use. Lymphoma, B-Cell, Marginal Zone / complications. Ribavirin / therapeutic use. Salivary Gland Neoplasms / complications
  • [MeSH-minor] Drug Therapy, Combination. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109616.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 49717AWG6K / Ribavirin; 9008-11-1 / Interferons
  •  go-up   go-down


9. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC: Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol; 2004;112(4):203-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.
  • Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001.
  • The sites of involvement were the parotid gland in 13, the submandibular gland in 9 and the minor salivary gland in 1.
  • The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient.
  • Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma.
  • Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma.
  • Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome.
  • All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment.
  • Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients.
  • These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy.
  • One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease.
  • Thus, salivary gland lymphoma proved to be an indolent disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Autoimmune Diseases / complications. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / complications. Male. Middle Aged. Radiotherapy. Remission Induction. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564732.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Sato K, Kawana M, Sato Y, Takahashi S: Malignant lymphoma in the head and neck associated with benign lymphoepithelial lesion of the parotid gland. Auris Nasus Larynx; 2002 Apr;29(2):209-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in the head and neck associated with benign lymphoepithelial lesion of the parotid gland.
  • Lymphoepithelial lesion is a benign lymphoproliferative disease occasionally arises in the salivary glands, but association with malignant diseases or autoimmune diseases has also been discussed.
  • We herein present three cases of malignant lymphoma arose in the parotid gland and the lacrimal gland, following parotid surgery for benign lymphoepithelial lesion (BLEL) of the parotid gland.
  • Two cases had mucosa associated lymphoid tissue (MALT) lymphoma in the parotid gland; one arose in the ipsilateral parotid gland as a recurrent swelling, and the other arose in the contralateral parotid gland of the previous BLEL surgery.
  • The third case of malignant lymphoma arose in the lacrimal gland on the ipsilateral side, and the following contralateral parotid gland remained BLEL.
  • All three patients were treated by chemotherapy and one patient received additional radiotherapy.
  • To follow-up lymphoproliferative diseases in the salivary glands such as BLEL, careful observation should be made on the same gland, other major salivary glands, and other organs in the head and neck, especially in females with autoimmune diseases.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Lymphoma, B-Cell, Marginal Zone / diagnosis. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Recurrence. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Benign Lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11893460.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Suh C, Huh J, Roh JL: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence. Oral Oncol; 2008 Oct;44(10):949-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence.
  • Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma, although generally indolent in nature, has variable and heterogeneous clinical course and biologic behavior.
  • Forty-four new patients with MALT lymphomas arising in ocular adnexa (24 patients, group A) and other head and neck sites (20 patients, group B) of the salivary gland (13), thyroid gland (3) and other regions (4) were retrospectively analyzed.
  • At initial diagnosis, 21 patients had solitary lesions (16/24 in the group A vs. 5/20 in the group B, P=.008); 23 had disseminated disease at multiple sites (11 patients) and/or lymph node involvement (15 patients: 3/24 in the group A vs. 12/20 in the group B, P=.025).
  • Treatment consisted of local therapy, consisting of surgical resection and/or radiotherapy, in 34 patients and systemic chemotherapy with/without local therapy in 10 patients.
  • Recurrence at prolonged times after therapy indicates the need for close long-term monitoring, and for prospective trials to prevent recurrence.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234544.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ: Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol; 2003 Nov 15;21(22):4157-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
  • PURPOSE: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a distinct lymphoma with unique clinicopathologic features.
  • We report the clinical outcome of stage I and II MALT lymphoma treated with involved field radiation therapy (RT).
  • Presenting sites were stomach (17 patients), orbital adnexa (31 patients), salivary glands (24 patients), thyroid gland (13 patients), and other sites (18 patients).
  • Ninety-three patients received RT--85 received RT alone, and eight received chemotherapy and RT--with a median dose of 30 Gy.
  • The median follow-up time was 5.1 years.
  • No relapses were observed in patients with stomach or thyroid lymphoma, whereas 14 of 63 patients (22%) experienced relapse in the other sites.
  • Transformed lymphoma was observed in 14% of patients (two of 14) experiencing relapse.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14615444.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


13. Krasić D, Radović P, Burić N, Cosić A, Katić V: [MALT lymphoma of the parotid salivary gland]. Vojnosanit Pregl; 2007 Jan;64(1):53-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the parotid salivary gland].
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma was described for the first time in 1983 by Isaacson and Wright.
  • It was classified into extranodal non-Hodkin's lymphomas of B-cell lymphocytes of the marginal zone of reactive lymphe follicles.
  • After the subtotal parotidectomy, using conservation of nerve facialis, the tissue blocks were fixed in 10% formaldehyde.
  • The paraffine sections were stained by routine histochemical and an immunohistochemical method by using monoclonal antibodies for both B-cell and T-cell lymphomas, due to the verification of lymphoepithelial lesions.
  • The MALT lymphoma diagnosis was based on the histological criteria and confirmed by an immunohistochemical method.
  • After the surgical therapy accompanied by chemotherapy, the patients were controlled at regular intervals, and residual MALT lymphoma did not appear.
  • CONCLUSION: MALT lymphoma is a rare tumor of the salivary glands, with the most frequent localization in the parotide gland.
  • The diagnosis was made pathohistologically and confirmed immunohistochemically.
  • The surgical therapy was accompained by adjuvant chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone. Parotid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304725.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


14. Troch M, Woehrer S, Streubel B, Weissel M, Hoffmann M, Müllauer L, Chott A, Raderer M: Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. Ann Oncol; 2008 Jul;19(7):1336-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma.
  • BACKGROUND: Autoimmune diseases have been implicated in the genesis of MALT lymphoma of various localizations.
  • The development of thyroidal MALT lymphoma has been described as an adverse event in patients suffering from long-standing chronic autoimmune thyroiditis (CAT, Hashimoto's thyroiditis).
  • The percentage and possible association between CAT and extrathyroidal MALT lymphoma, however, have not been assessed so far.
  • PATIENTS AND METHODS: A retrospective analysis of 80 patients with MALT lymphoma diagnosed and treated at our institution identified a total of 13 patients (16%) with MALT lymphoma suffering from an underlying CAT.
  • Four patients suffered from thyroidal lymphoma and nine patients had extrathyroidal lymphoma (four gastric, two orbital, one small intestinal and two salivary gland lymphomas).
  • Three patients had a long-standing history of CAT at diagnosis of MALT lymphoma, while CAT was discovered during staging and clinical work-up of MALT lymphoma in the remaining 10 patients.
  • Only one of the four patients with gastric MALT lymphoma responded to antibiotic treatment against Helicobacter pylori infection.
  • CONCLUSION: Our findings suggest that CAT is found in patients with not only thyroidal but also nonthyroidal MALT lymphoma.
  • While the nature of our data does not allow for delineation of a direct association between CAT and development of extrathyroidal MALT lymphoma, further prospective studies on this issue are warranted.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334510.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; N12000U13O / Doxycycline
  •  go-up   go-down


15. Gluth MB, Orvidas LJ: Bilateral cystic parotid masses and a hypopharyngeal mass: a case report and review of mucosa-associated lymphoid tissue lymphoma in the head and neck. Am J Otolaryngol; 2005 Mar-Apr;26(2):135-7
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral cystic parotid masses and a hypopharyngeal mass: a case report and review of mucosa-associated lymphoid tissue lymphoma in the head and neck.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell lymphoma that was first described in gastric mucosa.
  • Although presentation in the parotid gland is not unusual, bilateral cystic masses and associated hypopharyngeal involvement are rare.
  • Biopsy of the hypopharynx was consistent with MALT lymphoma.
  • The patient was treated with single-agent chemotherapy and had a good initial response.
  • MALT lymphoma occasionally originates within the salivary glands and other sites in the head and neck region.
  • This disease should be considered in the differential diagnosis of cystic or bilateral parotid masses and hypopharyngeal masses.
  • [MeSH-major] Cysts / radiography. Head and Neck Neoplasms / radiography. Hypopharynx / radiography. Lymphoma, B-Cell, Marginal Zone / radiography. Parotid Diseases / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chlorambucil / therapeutic use. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742269.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


16. Liao Z, Ha CS, McLaughlin P, Manning JT, Hess M, Cabanillas F, Cox JD: Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. Int J Radiat Oncol Biol Phys; 2000 Sep 1;48(2):399-403
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression.
  • PURPOSE: Mucosa-associated lymphoid tissue (MALT) lymphoma commonly presents in the gastrointestinal (GI) tract.
  • Supradiaphragmatic MALT lymphoma is less common and its natural history is not well defined.
  • This study was conducted to understand the natural history, to determine the frequency of synchronous disease in the GI tract, and to understand the patterns of disease progression after treatment for supradiaphragmatic MALT lymphoma.
  • PATIENTS AND METHODS: We retrospectively reviewed the medical records of 39 patients who presented with supradiaphragmatic MALT lymphoma between 1991 and 1997.
  • The most common primary site was salivary gland followed by ocular adnexa, lung, oral cavity, and others.
  • The initial treatments were: involved field radiation therapy (n = 10), chemotherapy (n = 14), combination of radiation therapy and chemotherapy (n = 9), observation after biopsy (n = 4), antibiotics only (n = 1), and patient refusal of further intervention (n = 1).
  • Seven patients received antibiotics as a part of the initial treatment.
  • Thirty-six patients achieved complete response (CR) to the initial treatment.
  • Of the 2 patients who relapsed in the stomach, 1 had negative EGD + Bx at the time of initial diagnosis.
  • CONCLUSION: Supradiaphragmatic MALT lymphoma appears to have a favorable prognosis.
  • However, routine evaluation of the stomach is recommended for patients who present with supradiaphragmatic MALT lymphoma at the time of initial evaluation and at the time of relapse.
  • Patients who failed initial therapy can be successfully salvaged with further treatment.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Time Factors. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974453.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M: Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1258-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II MALT lymphoma: results of treatment with radiotherapy.
  • PURPOSE: Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct disease with specific clinical and pathologic features that may affect diverse organs.
  • We analyzed our recent experience with Stage I/II MALT lymphoma presenting in the stomach and other organs to assess the outcome following involved field radiation therapy (RT).
  • Presenting sites included stomach, 15; orbital adnexa, 19; salivary glands, 15; thyroid, 8; lung, 5; upper airways, 3 (nasopharynx, 2; larynx, 1); urinary bladder, 3; breast, 1; and rectum, 1.
  • Sixty-two patients received radiation therapy: 52 received RT alone, 7 received chemotherapy and RT, and 3 received antibiotics followed by RT.
  • Median RT dose was 30 Gy (range, 17.5--35 Gy).
  • Most frequently used RT prescriptions were 25 Gy (26 patients-18 orbit, 6 stomach, and 2 salivary glands), 30 Gy (23 patients), and 35 Gy (8 patients).
  • Five patients had complete surgical excision of lymphoma and no other treatment (stomach 1, salivary 2, lung 2), whereas 2 patients with gastric lymphoma received antibiotics only.
  • One patient refused treatment and was excluded from the analysis of treatment outcome, leaving 69 patients with a median follow-up of 4.2 years (range, 0.3-11.4 years).
  • No relapses were observed in patients with stomach and thyroid lymphoma.
  • Among the 5 patients treated with surgery only, 2 relapsed locally (lung, and minor salivary gland).
  • Among 62 patients who received RT, 8 relapsed (2 salivary, 3 orbit, 1 nasopharynx, 1 larynx, 1 breast).
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chlorambucil / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prednisone / administration & dosage. Prognosis. Remission Induction. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483337.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2
  •  go-up   go-down


18. Amouri A, Chtourou L, Mnif L, Mdhaffar M, Abid M, Ayedi L, Daoud J, Elloumi M, Boudawara T, Tahri N: [MALT lymphoma of the rectum: a case report treated by radiotherapy]. Cancer Radiother; 2009 Jan;13(1):61-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the rectum: a case report treated by radiotherapy].
  • [Transliterated title] Lymphome de MALT du rectum : à propos d'un cas traité par irradiation.
  • The mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct clinical pathologic entity that develops in diverse anatomic locations such as the stomach, salivary gland, thyroid, lung, skin and breast.
  • To our knowledge, only ten cases of primary rectal MALT lymphoma have been reported in the literature.
  • We report a 46-year-old woman with rectal MALT lymphoma, which regressed after radiotherapy.
  • Microscopic and immunohistologic studies of the biopsy specimen showed typical features of low grade MALT lymphoma.
  • Upper endoscopy showed chronic gastritis with lymphoid follicles but without any infiltration of lymphoma cells.
  • No extra-intestinal involvement was found on the staging evaluation, which included computed tomography (CT) of the abdomen, chest, pelvis and a bone marrow biopsy.
  • Repeated colonoscopy 4 months after the end of treatment showed that the rectal tumor had not regressed.
  • Biopsy specimens confirmed the persistent infiltration of lymphoma cells.
  • The patient was considered to be a non-responder to eradication therapy and was indicated for radiotherapy.
  • He underwent a total of 34 Gy.
  • Complete regression was confirmed by colonoscopic and histologic examination at 2 months after the end of treatment.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Biopsy. Chronic Disease. Colonoscopy. Female. Gastritis / complications. Gastritis / diagnosis. Gastritis / drug therapy. Gastrointestinal Hemorrhage / etiology. Helicobacter Infections / complications. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Rare Diseases. Rectal Diseases / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101191.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 27
  •  go-up   go-down


19. MacDermed D, Thurber L, George TI, Hoppe RT, Le QT: Extranodal nonorbital indolent lymphomas of the head and neck: relationship between tumor control and radiotherapy. Int J Radiat Oncol Biol Phys; 2004 Jul 1;59(3):788-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor head-and-neck location was Waldeyer's ring, 14; salivary glands, 16; thyroid, 4; and other sites, 6.
  • The most common histologies were marginal zone lymphoma and follicular grade 2.
  • Patients received combinations of surgery, chemotherapy, and radiotherapy.
  • Local therapy included surgery alone in 6 patients, radiotherapy alone in 7, and surgery plus radiotherapy in 12.
  • Multivariate analysis revealed that significant prognostic factors for survival were tumor site (favoring salivary and thyroid, p = 0.02) and age (favoring younger, p = 0.04).
  • Patients with salivary and thyroid primary tumors had better survival compared with others.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Neoplasm Staging. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery. Radiotherapy Dosage. Retrospective Studies. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / radiotherapy. Salivary Gland Neoplasms / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15183482.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Malek SN, Hatfield AJ, Flinn IW: MALT Lymphomas. Curr Treat Options Oncol; 2003 Aug;4(4):269-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucosa-associated lymphoid tissue (MALT) lymphomas occur in a variety of organs, including the orbit, conjunctiva, salivary glands, skin, thyroid gland, lungs, stomach, and intestine.
  • Diagnosis is made by pathologic evaluation of a tissue biopsy.
  • Staging includes a history and physical, chemistries, computed tomography scan, and bone marrow biopsy.
  • Treatment is tailored to organ involvement and stage at presentation.
  • Eradication of Helicobacter pylori using a triple anti-H. pylori regimen approved by the US Food and Drug Administration is standard therapy for all H. pylori-positive gastric MALT lymphomas.
  • Endoscopic ultrasound- and computed tomography-staged gastric MALT stage IE tumors will achieve a complete response with this approach in approximately 60% to 90% of patients (the more superficial the tumor, the better the response).
  • Tumors with a significant high-grade component or large cell tumors with a minor low-grade MALT component should receive CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based chemotherapy.
  • Localized MALT lymphomas of the orbit, conjunctiva, salivary glands, and thyroid gland are treated successfully with radiotherapy.
  • Surgery as first-line therapy for gastric MALT lymphomas was replaced by attempts at organ preservation.
  • In the past, margin-free surgical excision or tumor debulking followed by radiation therapy and chemotherapy has been highly effective for gastric MALT lymphomas.
  • Therefore, surgical excision of large cell or bulky tumors of the stomach, thyroid, lung, and salivary gland, followed by adjuvant radiotherapy or chemotherapy, may still be an important consideration in selected patients.
  • Disseminated MALT lymphomas are incurable and are treated primarily with chemotherapy according to symptoms.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2002 May;55(5):346-51 [11986338.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):50-5 [11753078.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1087-90 [9322502.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):95-102 [11145257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1058-66 [11958902.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):997-1008 [11474283.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1059-68 [12449739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):657-63 [11849787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2541-4 [11895791.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):300-4 [7826922.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1600-9 [11250988.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):547-8 [12241663.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2524-9 [7595703.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:241-58 [11722987.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):559-62 [11237911.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):307-15 [10375087.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):928-34 [10533473.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Gut. 2001 Apr;48(4):454-60 [11247887.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1313-24 [8620403.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):97-104 [11902529.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] J Pathol. 2001 Mar;193(3):318-24 [11241410.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):355-62 [7619750.001]
  • [Cites] Curr Gastroenterol Rep. 2000 Dec;2(6):494-8 [11079052.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):88-95 [10419446.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 12943607.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Vasil'ev VI, Kokosadze NV, Logvinenko OA, Nikitin EA, Mitrikov BV, Rodionova EB, Varlamova EIu: [Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma]. Ter Arkh; 2008;80(5):76-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma].
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy. Methylprednisolone / administration & dosage. Salivation / drug effects. Sjogren's Syndrome / drug therapy. Submandibular Gland / drug effects
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Drug Therapy, Combination. Female. Follow-Up Studies. Glucocorticoids / administration & dosage. Humans. Immunologic Factors / administration & dosage. Middle Aged. Pulse Therapy, Drug. Rituximab

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590121.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Glucocorticoids; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


22. Matsumoto T, Iida M: [Extra-gastric lymphoma of MALT type and H. pylori eradication]. Nihon Rinsho; 2005 Nov;63 Suppl 11:308-11
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-gastric lymphoma of MALT type and H. pylori eradication].
  • [MeSH-major] Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / etiology. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / etiology. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / etiology
  • [MeSH-minor] Humans. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / etiology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363550.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down






Advertisement